Prognostic utility of HOXB13: IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

British Journal of Cancer

Volumn 104, Issue 11, 2011, Pages 1762-1769

  Jerevall, P L ^a   Ma, X J ^b   Li, H ^b   Salunga, R ^b   Kesty, N C ^b   Erlander, M G ^b   Sgroi, D C ^c   Holmlund, B ^a   Skoog, L ^d   Fornander, T ^d   Nordenskjold B ^a   Stal O ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Biotheranostics   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast Cancer Index; gene expression profiling; prognosis; recurrence; risk assessment

Indexed keywords

ESTROGEN RECEPTOR; HOX PROTEIN; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17 RECEPTOR BETA; PROTEIN HOXB13; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; EARLY CANCER; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MOLECULAR GRADE INDEX; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VALIDATION PROCESS;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SWEDEN; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 79957617088     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.145     Document Type: Article

References (20)

1. Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24740 breast cancer cases. Cancer 63: 181-187 (Pubitemid 19032001)
2. Desmedt C, Sotiriou C (2006) Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle 5: 2198-2202 (Pubitemid 44546553)
3. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355: 560-569 (Pubitemid 44200649)
4. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207-219
5. Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ (2006) A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12: 2080-2087
6. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thurlimann B, Senn HJ (2006) First-select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17: 1772-1776 (Pubitemid 44884051)
7. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329
8. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge Jr GW, Perez EA, Shulman LN, Martino S, Sparano JA (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26: 4063-4071
9. Jerevall PL, Brommesson S, Strand C, Gruvberger-Saal S, Malmstrom P, Nordenskjold B, Wingren S, Soderkvist P, Ferno M, Stal O (2008) Exploring the two-gene ratio in breast cancer - independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat 107: 225-234 (Pubitemid 350265690)
10. Jerevall PL, Jansson A, Fornander T, Skoog L, Nordenskjold B, Stal O (2010) Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer. Breast Cancer Res 12: R53
11. Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA, Osborne CK, Allred DC, Erlander MG (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 24: 4611-4619 (Pubitemid 46630959)
12. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris A, Goss P, Sotiriou C, Erlander M, Sgroi D (2008) A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 14: 2601-2608
13. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5: 607-616 (Pubitemid 38748922)
14. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826 (Pubitemid 40051905)
15. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904 (Pubitemid 27330017)
16. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19: 980-991 (Pubitemid 32176272)
17. Rutqvist LE, Johansson H (2007) Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncologica (Stockholm, Sweden) 46: 133-145 (Pubitemid 46277056)
18. Van't Veer LJ, Bernards R (2008) Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452: 564-570 (Pubitemid 351483370)
19. Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, Van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009 (Pubitemid 35461656)
20. Wrange O, Nordenskjöld B, Gustafsson JA (1978) Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Anal Biochem 85: 461-475 (Pubitemid 9059206)